SB
Samsara BioCapital Portfolio holdings
AUM
$489M
This Quarter Return
-13.51%
1 Year Return
+135.25%
3 Year Return
+909.96%
5 Year Return
+774.56%
10 Year Return
–
AUM
$561M
AUM Growth
+$561M
(-23%)
Cap. Flow
+$45.2M
Cap. Flow
% of AUM
8.06%
Top 10 Holdings %
Top 10 Hldgs %
86.32%
Holding
44
New
1
Increased
3
Reduced
8
Closed
7
Top Buys
| 1 |
KLRS
Kalaris Therapeutics, Inc. Common Stock
KLRS
|
$91.3M |
| 2 |
Mineralys Therapeutics
MLYS
|
$9.53M |
| 3 |
Surrozen
SRZN
|
$2.81M |
| 4 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$2.2M |
Top Sells
| 1 |
Jasper Therapeutics
JSPR
|
$12.5M |
| 2 |
LENZ
LENZ Therapeutics
LENZ
|
$11.8M |
| 3 |
Arcellx
ACLX
|
$7.76M |
| 4 |
Aclaris Therapeutics
ACRS
|
$5.91M |
| 5 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$4.7M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Scholar Rock
SRRK
$3.14B
| $180M | 32.18% | 5,612,896 | – | – |
|
|
KLRS
2
Kalaris Therapeutics, Inc. Common Stock
KLRS
$76.3M
| $91.9M | 16.39% | 11,448,081 +11,365,745 | +13,804% | +$91.3M |
|
|
3
Mineralys Therapeutics
MLYS
$1.03B
| $90.1M | 16.07% | 5,674,916 +600,000 | +12% | +$9.53M |
|
4
Neurogene
NGNE
$264M
| $20.1M | 3.59% | 1,717,127 | – | – |
|
|
ALMS
5
Alumis Inc. Common Stock
ALMS
$479M
| $20.1M | 3.58% | 3,266,498 | – | – |
|
|
PVLA
6
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $19M | 3.39% | 679,486 | – | – |
|
|
SEPN
7
Septerna, Inc. Common Stock
SEPN
$539M
| $18.2M | 3.25% | 3,149,128 +380,608 | +14% | +$2.2M |
|
|
CRGX
8
DELISTED
CARGO Therapeutics
CRGX
| $18M | 3.2% | 4,415,689 | – | – |
|
|
LENZ
9
LENZ Therapeutics
LENZ
$1.1B
| $13.5M | 2.41% | 526,390 -460,591 | -47% | -$11.8M |
|
|
UPB
10
Upstream Bio, Inc. Common Stock
UPB
$923M
| $12.7M | 2.26% | 2,067,146 -150,000 | -7% | -$918K |
|
|
11
Arcellx
ACLX
$3.85B
| $8.87M | 1.58% | 135,276 -118,365 | -47% | -$7.76M |
|
12
Zymeworks
ZYME
$1.12B
| $7.94M | 1.42% | 666,667 -333,333 | -33% | -$3.97M |
|
|
AVDL
13
Avadel Pharmaceuticals
AVDL
$1.43B
| $7.58M | 1.35% | 967,527 | – | – |
|
14
Rhythm Pharmaceuticals
RYTM
$6.85B
| $7.32M | 1.3% | 138,118 -34,529 | -20% | -$1.83M |
|
15
Nkarta
NKTX
$151M
| $6.93M | 1.24% | 3,768,035 | – | – |
|
16
Gossamer Bio
GOSS
$562M
| $6.74M | 1.2% | 6,130,268 | – | – |
|
|
SLRN
17
DELISTED
ACELYRIN
SLRN
| $6.23M | 1.11% | 2,523,022 | – | – |
|
|
CTNM
18
Contineum Therapeutics
CTNM
$293M
| $4.11M | 0.73% | 588,816 | – | – |
|
19
vTv Therapeutics
VTVT
$42.5M
| $3.58M | 0.64% | 206,784 | – | – |
|
|
OKUR
20
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $3.54M | 0.63% | 824,155 | – | – |
|
|
21
Surrozen
SRZN
$104M
| $2.81M | 0.5% | +241,400 | New | +$2.81M |
|
|
ABVX
22
Abivax
ABVX
$6.12B
| $2.66M | 0.47% | 425,000 -425,000 | -50% | -$2.66M |
|
23
Sutro Biopharma
STRO
$72.7M
| $1.43M | 0.25% | 2,196,814 | – | – |
|
|
INZY
24
DELISTED
Inozyme Pharma
INZY
| $1.42M | 0.25% | 1,562,500 | – | – |
|
|
ARTV
25
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.7M
| $875K | 0.16% | 291,666 | – | – |
|